<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diabetes Management - ICRP OSCE Preparation</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            line-height: 1.6;
            color: #333;
            background: #f5f5f5;
            padding: 20px;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            padding: 40px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
            border-radius: 8px;
        }

        .breadcrumbs {
            background: #2c3e50;
            color: white;
            padding: 15px 20px;
            margin: -40px -40px 30px -40px;
            border-radius: 8px 8px 0 0;
            font-size: 14px;
        }

        .breadcrumbs a {
            color: #3498db;
            text-decoration: none;
        }

        .breadcrumbs a:hover {
            text-decoration: underline;
        }

        .breadcrumbs span {
            margin: 0 8px;
            color: #95a5a6;
        }

        .quick-nav {
            background: #ecf0f1;
            padding: 20px;
            margin-bottom: 30px;
            border-left: 4px solid #3498db;
            border-radius: 4px;
        }

        .quick-nav h3 {
            color: #2c3e50;
            margin-bottom: 15px;
            font-size: 18px;
        }

        .quick-nav ul {
            list-style: none;
        }

        .quick-nav li {
            margin: 8px 0;
        }

        .quick-nav a {
            color: #2980b9;
            text-decoration: none;
        }

        .quick-nav a:hover {
            color: #3498db;
            text-decoration: underline;
        }

        h1 {
            color: #2c3e50;
            margin-bottom: 20px;
            padding-bottom: 15px;
            border-bottom: 3px solid #3498db;
            font-size: 2.5em;
        }

        h2 {
            color: #34495e;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid #bdc3c7;
            font-size: 1.8em;
        }

        h3 {
            color: #34495e;
            margin-top: 30px;
            margin-bottom: 15px;
            font-size: 1.4em;
        }

        h4 {
            color: #34495e;
            margin-top: 25px;
            margin-bottom: 12px;
            font-size: 1.2em;
        }

        p {
            margin-bottom: 15px;
            line-height: 1.8;
        }

        ul, ol {
            margin: 15px 0 15px 30px;
        }

        li {
            margin: 8px 0;
            line-height: 1.8;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 25px 0;
            font-size: 14px;
            box-shadow: 0 2px 5px rgba(0,0,0,0.1);
        }

        th {
            background: #3498db;
            color: white;
            padding: 12px;
            text-align: left;
            font-weight: 600;
        }

        td {
            padding: 12px;
            border-bottom: 1px solid #ddd;
        }

        tr:hover {
            background: #f5f5f5;
        }

        .alert {
            padding: 20px;
            margin: 20px 0;
            border-radius: 5px;
            border-left: 5px solid;
        }

        .alert-success {
            background: #d4edda;
            border-color: #28a745;
            color: #155724;
        }

        .alert-info {
            background: #d1ecf1;
            border-color: #17a2b8;
            color: #0c5460;
        }

        .alert-warning {
            background: #fff3cd;
            border-color: #ffc107;
            color: #856404;
        }

        .alert-danger {
            background: #f8d7da;
            border-color: #dc3545;
            color: #721c24;
        }

        .script-box {
            background: #e8f4f8;
            border-left: 4px solid #17a2b8;
            padding: 15px;
            margin: 15px 0;
            border-radius: 4px;
        }

        .mistake-box {
            background: #ffe6e6;
            border-left: 4px solid #dc3545;
            padding: 15px;
            margin: 15px 0;
            border-radius: 4px;
        }

        .tip-box {
            background: #fff8e1;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin: 15px 0;
            border-radius: 4px;
        }

        footer {
            margin-top: 50px;
            padding-top: 20px;
            border-top: 2px solid #ecf0f1;
            text-align: center;
            color: #7f8c8d;
            font-size: 14px;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="breadcrumbs">
            <a href="../../START_HERE.html">Home</a>
            <span>‚Ä∫</span>
            <a href="../00_MASTER_INDEX_AMC_CLINICAL_OSCE.html">OSCE Preparation</a>
            <span>‚Ä∫</span>
            <a href="01_Cardiovascular_Respiratory_History.html">Medicine</a>
            <span>‚Ä∫</span>
            <span>Diabetes Management</span>
        </div>

        <h1>Endocrinology: Diabetes Management</h1>

        <div class="alert alert-info">
            <strong>OSCE Context:</strong> Diabetes management is heavily tested in AMC Part 2 Clinical and ICRP examinations. Expect stations on newly diagnosed diabetes counselling, medication management, diabetic emergencies, and complications assessment. Time allocation: 8 minutes per station.
        </div>

        <div class="quick-nav">
            <h3>Quick Navigation</h3>
            <ul>
                <li><a href="#overview">Module Overview</a></li>
                <li><a href="#history">History Taking - New Diabetes Diagnosis</a></li>
                <li><a href="#emergencies">Diabetic Emergencies</a>
                    <ul style="margin-left: 20px;">
                        <li><a href="#dka">DKA</a></li>
                        <li><a href="#hhs">HHS</a></li>
                        <li><a href="#hypo">Hypoglycaemia</a></li>
                    </ul>
                </li>
                <li><a href="#medications">Medication Management</a></li>
                <li><a href="#complications">Complications Assessment</a></li>
                <li><a href="#osce-stations">OSCE Practice Stations</a></li>
                <li><a href="#counseling">Counselling Scripts</a></li>
                <li><a href="#guidelines">Australian Guidelines Summary</a></li>
                <li><a href="#mistakes">Common IMG Mistakes</a></li>
                <li><a href="#references">Quick Reference Tables</a></li>
            </ul>
        </div>

        <h2 id="overview">MODULE OVERVIEW</h2>

        <p><strong>Purpose:</strong> This module provides comprehensive diabetes management content for ICRP candidates preparing for AMC Part 2 Clinical OSCE examinations. Content is aligned with Australian clinical practice, eTG 2024 guidelines, and AHPRA standards.</p>

        <p><strong>Scope:</strong></p>
        <ul>
            <li>Type 1 and Type 2 Diabetes Mellitus</li>
            <li>Diabetic emergencies (DKA, HHS, Hypoglycaemia)</li>
            <li>Medication management (Australian PBS context)</li>
            <li>Complications screening and management</li>
            <li>Patient counselling and education</li>
        </ul>

        <p><strong>Key Australian Resources:</strong></p>
        <ul>
            <li><strong>NDSS (National Diabetes Services Scheme):</strong> Free/subsidised diabetes supplies - MANDATORY referral</li>
            <li><strong>eTG 2024:</strong> Therapeutic Guidelines for diabetes management</li>
            <li><strong>PBS:</strong> Pharmaceutical Benefits Scheme criteria for medication access</li>
            <li><strong>RACGP Guidelines:</strong> General practice diabetes management</li>
            <li><strong>Diabetes Australia:</strong> Patient education resources</li>
        </ul>

        <h2 id="history">PART 1: HISTORY TAKING - NEW DIABETES DIAGNOSIS</h2>

        <h3>Opening Statement (30 seconds)</h3>

        <div class="script-box">
            <p><strong>Opening Script:</strong></p>
            <p>"Good morning/afternoon, I'm Dr [Name]. Before we begin, can I confirm your name and date of birth? Thank you. I understand you've been referred because of some blood test results showing high sugar levels. I'd like to ask you some questions about any symptoms you've been experiencing and your general health. This will take about 5-6 minutes. Is that alright with you?"</p>
        </div>

        <div class="tip-box">
            <p><strong>Differential Thinking (Immediate):</strong> High blood glucose could indicate:</p>
            <ol>
                <li><strong>Type 2 Diabetes</strong> (MOST LIKELY if age >40, overweight, gradual onset)</li>
                <li><strong>Type 1 Diabetes</strong> (if age <30, acute onset, thin, DKA presentation)</li>
                <li><strong>Secondary causes</strong> (medications, pancreatitis, Cushing's syndrome)</li>
            </ol>
        </div>

        <h3>Focused History (4-5 minutes)</h3>

        <h4>A. Classic Diabetes Symptoms - The FOUR Ps</h4>

        <p><strong>Mnemonic: FOUR Ps</strong></p>
        <ul>
            <li><strong>Polyuria</strong> - Excessive urination</li>
            <li><strong>Polydipsia</strong> - Excessive thirst</li>
            <li><strong>Polyphagia</strong> - Excessive hunger (less common in Type 2)</li>
            <li><strong>(Weight loss)</strong> - Unexplained weight loss (Type 1 >> Type 2)</li>
        </ul>

        <div class="script-box">
            <p><strong>Screening Questions (Say out loud):</strong></p>
            <ul>
                <li>"Have you noticed you're passing urine more frequently than usual? How many times during the night?" (Polyuria - normal 0-1x, diabetes 3-5x)</li>
                <li>"Have you been feeling unusually thirsty? How much water are you drinking per day?" (Polydipsia - >3L suggests diabetes)</li>
                <li>"Have you noticed any changes in your appetite or weight recently?" (Weight loss + polyphagia in Type 1)</li>
                <li>"Have you been feeling more tired than usual?" (Fatigue from hyperglycaemia)</li>
                <li>"Any blurred vision?" (Osmotic lens changes)</li>
                <li>"Any slow-healing cuts or skin infections?" (Impaired immunity)</li>
                <li>"In men: Any problems with sexual function?" (Erectile dysfunction from neuropathy/vascular disease)</li>
            </ul>
        </div>

        <h4>B. Type 1 vs Type 2 Differentiation</h4>

        <table>
            <thead>
                <tr>
                    <th>Feature</th>
                    <th>Type 1 Diabetes</th>
                    <th>Type 2 Diabetes</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Age at onset</strong></td>
                    <td>Usually <30 years (can occur at any age)</td>
                    <td>Usually >40 years (increasingly younger)</td>
                </tr>
                <tr>
                    <td><strong>Onset</strong></td>
                    <td>Acute (days to weeks)</td>
                    <td>Gradual (months to years)</td>
                </tr>
                <tr>
                    <td><strong>Body habitus</strong></td>
                    <td>Usually lean/normal weight</td>
                    <td>Often overweight/obese (BMI >30)</td>
                </tr>
                <tr>
                    <td><strong>Ketosis</strong></td>
                    <td>Prone to DKA</td>
                    <td>Rare (unless severe stress)</td>
                </tr>
                <tr>
                    <td><strong>Insulin</strong></td>
                    <td>ALWAYS required</td>
                    <td>Often managed with oral agents initially</td>
                </tr>
                <tr>
                    <td><strong>Family history</strong></td>
                    <td>Less common (10-15%)</td>
                    <td>Very common (>60%)</td>
                </tr>
                <tr>
                    <td><strong>Autoantibodies</strong></td>
                    <td>Positive (GAD, IA-2, ZnT8)</td>
                    <td>Negative</td>
                </tr>
            </tbody>
        </table>

        <h4>C. Risk Factors Assessment</h4>

        <div class="script-box">
            <p><strong>Risk Factor Questions:</strong></p>
            <ul>
                <li>"Does anyone in your family have diabetes?" (First-degree relative increases risk 2-6x)</li>
                <li>"What's your current weight and height? Have you gained weight recently?" (BMI >30, central obesity)</li>
                <li>"What's your ethnic background?" (Aboriginal/Torres Strait Islander, Pacific Islander, South Asian, Middle Eastern - higher risk)</li>
                <li>"For women: Have you ever had gestational diabetes or large babies (>4.5kg)?" (GDM = 50% risk Type 2 within 10 years)</li>
                <li>"Do you have PCOS or irregular periods?" (Insulin resistance)</li>
                <li>"Have you been diagnosed with high blood pressure or cholesterol?" (Metabolic syndrome)</li>
                <li>"Are you taking any regular medications?" (Steroids, antipsychotics can cause hyperglycaemia)</li>
            </ul>
        </div>

        <h4>D. Complications Screening</h4>

        <p><strong>Microvascular Complications:</strong></p>
        <ul>
            <li><strong>Eyes (Retinopathy):</strong> "Any changes in your vision? Floaters? Difficulty reading?"</li>
            <li><strong>Kidneys (Nephropathy):</strong> "Any swelling in your legs? Foamy urine?"</li>
            <li><strong>Nerves (Neuropathy):</strong> "Any numbness, tingling, or pain in your feet or hands?"</li>
        </ul>

        <p><strong>Macrovascular Complications:</strong></p>
        <ul>
            <li><strong>CVD:</strong> "Any chest pain, shortness of breath with exertion?"</li>
            <li><strong>PVD:</strong> "Any pain in your calves when walking? Coldness in feet?"</li>
            <li><strong>Stroke:</strong> "Any weakness, speech problems, dizziness?"</li>
        </ul>

        <h4>E. Medications, Allergies, Social History</h4>

        <ul>
            <li><strong>Current medications:</strong> Especially steroids, thiazides, antipsychotics</li>
            <li><strong>Allergies:</strong> Document clearly</li>
            <li><strong>Smoking:</strong> Quantify pack-years (accelerates complications)</li>
            <li><strong>Alcohol:</strong> Units per week (hypoglycaemia risk)</li>
            <li><strong>Exercise:</strong> Current activity level</li>
            <li><strong>Diet:</strong> General eating patterns</li>
            <li><strong>Occupation:</strong> Driving (licensing implications), shift work</li>
        </ul>

        <h3>Summary to Examiner (60 seconds)</h3>

        <div class="script-box">
            <p><strong>Presentation Format:</strong></p>
            <p>"This is a [age]-year-old [gender] presenting with [duration] history of polyuria and polydipsia.</p>
            <p>Key features include: [Feature 1], [Feature 2], [Feature 3]</p>
            <p>My leading diagnosis is <strong>Type 2 Diabetes Mellitus</strong> based on [age >40, gradual onset, BMI, family history].</p>
            <p>Alternative diagnoses to consider: [Type 1 if atypical features, secondary causes]</p>
            <p>My management plan would include:</p>
            <ul>
                <li>Confirm diagnosis: Fasting glucose, HbA1c, random glucose if symptomatic</li>
                <li>Baseline investigations: Lipids, renal function, urinary ACR</li>
                <li>Commence lifestyle modification counselling</li>
                <li>Consider Metformin if HbA1c >48 mmol/mol (eTG first-line)</li>
                <li>Refer to NDSS (National Diabetes Services Scheme)</li>
                <li>Arrange diabetes education and dietitian review</li>
                <li>Screen for complications annually</li>
            </ul>"
        </div>

        <h2 id="emergencies">PART 2: DIABETIC EMERGENCIES</h2>

        <div class="alert alert-danger">
            <strong>‚ö†Ô∏è EMERGENCY RECOGNITION:</strong> Diabetic emergencies are life-threatening. Immediate recognition and management required. Always assess ABCDE approach first.
        </div>

        <h3 id="dka">A. Diabetic Ketoacidosis (DKA)</h3>

        <h4>Definition & Diagnostic Criteria</h4>

        <p><strong>DKA Triad (ALL THREE required):</strong></p>
        <ol>
            <li><strong>Hyperglycaemia:</strong> Blood glucose >11 mmol/L (usually >20 mmol/L)</li>
            <li><strong>Ketosis:</strong> Blood ketones >3 mmol/L OR ketonuria 2+</li>
            <li><strong>Acidosis:</strong> pH <7.3 OR bicarbonate <15 mmol/L</li>
        </ol>

        <h4>Clinical Presentation</h4>

        <p><strong>Symptoms (develop over 24-48 hours):</strong></p>
        <ul>
            <li>Polyuria and polydipsia (osmotic diuresis)</li>
            <li>Nausea and vomiting</li>
            <li>Abdominal pain (can mimic acute abdomen)</li>
            <li>Weakness and fatigue</li>
            <li>Confusion or altered consciousness</li>
        </ul>

        <p><strong>Signs:</strong></p>
        <ul>
            <li><strong>Kussmaul breathing:</strong> Deep, rapid respirations (compensating for acidosis)</li>
            <li><strong>Ketotic breath:</strong> Fruity/acetone smell</li>
            <li><strong>Dehydration:</strong> Dry mucous membranes, reduced skin turgor, tachycardia, hypotension</li>
            <li><strong>Altered mental state:</strong> Confusion to coma (if severe)</li>
        </ul>

        <h4>Common Precipitants (The 5 I's)</h4>

        <ul>
            <li><strong>Infection:</strong> UTI, pneumonia, gastroenteritis (MOST COMMON)</li>
            <li><strong>Insufficient insulin:</strong> Missed doses, pump failure, new diagnosis</li>
            <li><strong>Infarction:</strong> MI, stroke, mesenteric ischaemia</li>
            <li><strong>Intoxication:</strong> Alcohol, drugs</li>
            <li><strong>Pregnancy:</strong> Lower threshold for ketosis</li>
        </ul>

        <h4>Management (Australian eTG Protocol)</h4>

        <div class="alert alert-danger">
            <p><strong>IMMEDIATE ACTIONS:</strong></p>
            <ol>
                <li><strong>Call for senior help</strong> - Medical emergency</li>
                <li><strong>ABCDE assessment</strong> - Airway, Breathing, Circulation, Disability, Exposure</li>
                <li><strong>High-flow oxygen</strong> if hypoxic</li>
                <li><strong>IV access</strong> - Two large-bore cannulae</li>
                <li><strong>Blood tests:</strong> VBG/ABG, glucose, ketones, U&Es, FBC, cultures</li>
                <li><strong>ECG:</strong> Check for hyperkalaemia, MI</li>
                <li><strong>Urinalysis and culture</strong></li>
            </ol>
        </div>

        <p><strong>Fluid Resuscitation (PRIORITY):</strong></p>
        <ul>
            <li><strong>0.9% NaCl:</strong> 1L over 1 hour, then 1L over 2 hours, then 1L over 4 hours</li>
            <li>Typical deficit: 5-10 litres</li>
            <li>Monitor BP, urine output, JVP</li>
            <li>Switch to 0.9% NaCl + 5% dextrose when glucose <15 mmol/L</li>
        </ul>

        <p><strong>Insulin (AFTER fluid resuscitation started):</strong></p>
        <ul>
            <li><strong>Fixed-rate IV insulin infusion:</strong> 0.1 units/kg/hour (typically 5-7 units/hour for 70kg adult, maximum initial rate 15 units/hour)</li>
            <li>Continue long-acting insulin if already on it</li>
            <li><strong>CRITICAL SAFETY - BSL drop rate:</strong> Target drop 3-5 mmol/L/hour. <strong>NEVER &gt;5 mmol/L/hour</strong> due to cerebral oedema risk (especially in children and young adults)</li>
            <li><strong>When to add dextrose:</strong> When BSL reaches 12-15 mmol/L, add 5-10% dextrose to IV fluids and CONTINUE insulin infusion to clear ketones. DO NOT stop insulin until ketones cleared AND patient eating/drinking</li>
            <li>Aim to reduce ketones by 0.5 mmol/L/hour</li>
        </ul>

        <p><strong>Potassium Replacement (CRITICAL):</strong></p>
        <ul>
            <li>Insulin drives K+ into cells ‚Üí hypokalaemia</li>
            <li>Add 40 mmol KCl to each litre of IV fluid if K+ <5.5 mmol/L</li>
            <li>Monitor K+ every 1-2 hours initially</li>
        </ul>

        <p><strong>Monitoring:</strong></p>
        <ul>
            <li>Hourly: Glucose, ketones, vital signs</li>
            <li>2-hourly: VBG (pH, bicarbonate, K+)</li>
            <li>Fluid balance chart (risk of cerebral oedema if too rapid correction)</li>
        </ul>

        <div class="alert alert-danger">
            <p><strong>üö® ICU REFERRAL CRITERIA FOR DKA (ANY of the following):</strong></p>
            <ol>
                <li><strong>pH <7.1</strong> (severe acidosis)</li>
                <li><strong>HCO3 <5 mmol/L</strong> (severe bicarbonate depletion)</li>
                <li><strong>GCS <12 or deteriorating consciousness</strong> (cerebral oedema risk)</li>
                <li><strong>K+ <3.0 mmol/L despite replacement</strong> (refractory hypokalaemia - arrhythmia risk)</li>
                <li><strong>Acute kidney injury:</strong> Creatinine >200 Œºmol/L or oliguria <0.5mL/kg/hour</li>
                <li><strong>Hypotension despite adequate fluids</strong> (SBP <90 mmHg after 2L fluid)</li>
                <li><strong>Severe Kussmaul breathing with respiratory fatigue</strong> (unable to compensate for acidosis)</li>
                <li><strong>Oxygen saturation <92% on room air</strong> (respiratory compromise)</li>
                <li><strong>Pregnancy with ANY DKA</strong> (high fetal mortality - immediate ICU)</li>
                <li><strong>Age <18 years</strong> (cerebral oedema risk - 0.5-1% mortality in children)</li>
            </ol>
            <p><strong>Kussmaul Breathing:</strong> Deep, rapid, laboured respirations (rate 20-40/min) attempting to blow off CO2 to compensate for metabolic acidosis. If patient tiring = respiratory failure imminent = ICU NOW</p>
        </div>

        <p><strong>Resolution Criteria (ALL required):</strong></p>
        <ul>
            <li>Blood ketones <0.6 mmol/L</li>
            <li>pH >7.3</li>
            <li>Bicarbonate >18 mmol/L</li>
            <li>Patient eating and drinking</li>
        </ul>

        <h3 id="hhs">B. Hyperosmolar Hyperglycaemic State (HHS)</h3>

        <h4>Definition & Diagnostic Criteria</h4>

        <ul>
            <li><strong>Severe hyperglycaemia:</strong> >30 mmol/L (often >40 mmol/L)</li>
            <li><strong>Hyperosmolality:</strong> Serum osmolality >320 mOsm/kg</li>
            <li><strong>No significant ketosis:</strong> Blood ketones <3 mmol/L, pH >7.3</li>
            <li><strong>Severe dehydration:</strong> Fluid deficit 8-12 litres</li>
        </ul>

        <h4>DKA vs HHS Comparison</h4>

        <table>
            <thead>
                <tr>
                    <th>Feature</th>
                    <th>DKA</th>
                    <th>HHS</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Diabetes type</strong></td>
                    <td>Type 1 (mainly)</td>
                    <td>Type 2 (mainly)</td>
                </tr>
                <tr>
                    <td><strong>Onset</strong></td>
                    <td>Hours to days</td>
                    <td>Days to weeks</td>
                </tr>
                <tr>
                    <td><strong>Glucose</strong></td>
                    <td>>11 mmol/L (usually 15-30)</td>
                    <td>>30 mmol/L (often >40)</td>
                </tr>
                <tr>
                    <td><strong>Ketones</strong></td>
                    <td>>3 mmol/L (significant)</td>
                    <td><3 mmol/L (minimal)</td>
                </tr>
                <tr>
                    <td><strong>pH</strong></td>
                    <td><7.3 (acidotic)</td>
                    <td>>7.3 (normal or mildly acidotic)</td>
                </tr>
                <tr>
                    <td><strong>Osmolality</strong></td>
                    <td>Variable</td>
                    <td>>320 mOsm/kg (very high)</td>
                </tr>
                <tr>
                    <td><strong>Consciousness</strong></td>
                    <td>Alert to drowsy</td>
                    <td>Often markedly reduced</td>
                </tr>
                <tr>
                    <td><strong>Dehydration</strong></td>
                    <td>Moderate (5-8L)</td>
                    <td>Severe (8-12L)</td>
                </tr>
                <tr>
                    <td><strong>Mortality</strong></td>
                    <td><5% (with treatment)</td>
                    <td>15-20% (higher)</td>
                </tr>
            </tbody>
        </table>

        <h4>Management (Australian eTG)</h4>

        <p><strong>Fluid Resuscitation (CRITICAL - Slower than DKA):</strong></p>
        <ul>
            <li><strong>0.9% NaCl:</strong> 1L over first hour IF haemodynamically stable AND no cardiac history</li>
            <li>Then 500mL/hour for 4 hours, then 250mL/hour</li>
            <li><strong>Elderly/cardiac patients:</strong> Start 500mL/hour and monitor for fluid overload. Consider CVP monitoring if concerns</li>
            <li><strong>CRITICAL SAFETY - Sodium correction:</strong> Correct at max 10 mmol/L per 24 hours to prevent osmotic demyelination syndrome (central pontine myelinolysis)</li>
            <li><strong>Monitor Na+ closely</strong> - slower correction than DKA due to higher osmotic demyelination risk</li>
        </ul>

        <p><strong>Key Differences from DKA:</strong></p>
        <ul>
            <li><strong>Slower fluid replacement:</strong> Risk of cerebral oedema, cardiac failure, osmotic demyelination</li>
            <li><strong>Lower insulin doses:</strong> 0.05 units/kg/hour (half of DKA dose)</li>
            <li><strong>Thromboprophylaxis ESSENTIAL:</strong> LMWH (high VTE risk due to hyperosmolality and dehydration)</li>
            <li><strong>Careful monitoring:</strong> Osmolality should not fall >3 mOsm/kg/hour</li>
        </ul>

        <h3 id="hypo">C. Hypoglycaemia</h3>

        <h4>Definition</h4>

        <p><strong>Blood glucose <4.0 mmol/L</strong> (some guidelines use <3.9 mmol/L)</p>

        <p><strong>Severe hypoglycaemia:</strong> Requiring assistance from another person</p>

        <h4>Whipple's Triad (Diagnostic Criteria)</h4>

        <ol>
            <li>Symptoms consistent with hypoglycaemia</li>
            <li>Documented low blood glucose <4.0 mmol/L</li>
            <li>Relief of symptoms with glucose administration</li>
        </ol>

        <h4>Clinical Presentation</h4>

        <p><strong>Autonomic Symptoms (early warning):</strong></p>
        <ul>
            <li>Sweating</li>
            <li>Tremor</li>
            <li>Palpitations</li>
            <li>Hunger</li>
            <li>Anxiety</li>
        </ul>

        <p><strong>Neuroglycopenic Symptoms (brain glucose deprivation):</strong></p>
        <ul>
            <li>Confusion</li>
            <li>Drowsiness</li>
            <li>Difficulty concentrating</li>
            <li>Visual disturbance</li>
            <li>Slurred speech</li>
            <li>Seizures (if severe)</li>
            <li>Coma (if severe)</li>
        </ul>

        <h4>Severity Classification</h4>

        <table>
            <thead>
                <tr>
                    <th>Severity</th>
                    <th>Features</th>
                    <th>Treatment</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Mild</strong></td>
                    <td>Autonomic symptoms, fully conscious, able to self-treat</td>
                    <td>15-20g quick-acting carbs orally</td>
                </tr>
                <tr>
                    <td><strong>Moderate</strong></td>
                    <td>Neuroglycopenic symptoms, conscious but needs help</td>
                    <td>15-20g quick-acting carbs (given by helper) + complex carbs</td>
                </tr>
                <tr>
                    <td><strong>Severe</strong></td>
                    <td>Unconscious, seizure, or unable to take oral</td>
                    <td>IV 10% glucose 150-200ml OR IM glucagon 1mg</td>
                </tr>
            </tbody>
        </table>

        <h4>Management: The 15-15 Rule</h4>

        <div class="alert alert-warning">
            <p><strong>15-15 RULE (Australian Standard):</strong></p>
            <ol>
                <li><strong>Give 15 grams of quick-acting carbohydrate:</strong>
                    <ul>
                        <li>3-4 glucose tablets (5g each)</li>
                        <li>150ml fruit juice</li>
                        <li>6-7 jelly beans</li>
                        <li>3 teaspoons sugar/honey</li>
                    </ul>
                </li>
                <li><strong>Wait 15 minutes</strong></li>
                <li><strong>Recheck blood glucose</strong></li>
                <li><strong>If still <4.0 mmol/L:</strong> Repeat 15g carbs</li>
                <li><strong>Once >4.0 mmol/L:</strong> Give complex carbohydrate (sandwich, crackers)</li>
            </ul>
        </div>

        <p><strong>Severe Hypoglycaemia (Unconscious/Seizure - Hospital/Emergency):</strong></p>
        <ul>
            <li><strong>IF IV ACCESS AVAILABLE:</strong>
                <ul>
                    <li>50mL 50% dextrose IV (preferred)</li>
                    <li>OR 100mL 25% dextrose IV</li>
                    <li>OR 150mL 10% dextrose IV (if large vein unavailable)</li>
                    <li>Give over 15 minutes, flush line with 0.9% saline after</li>
                </ul>
            </li>
            <li><strong>IF NO IV ACCESS:</strong>
                <ul>
                    <li>Glucagon 1mg IM (deltoid or lateral thigh)</li>
                    <li><strong>CONTRAINDICATIONS TO GLUCAGON:</strong>
                        <ul>
                            <li>Alcohol-related hypoglycaemia (glycogen stores depleted - glucagon ineffective, MUST use IV dextrose)</li>
                            <li>Prolonged fasting >48 hours (no glycogen stores)</li>
                            <li>Adrenal insufficiency (cannot mobilize glucose)</li>
                            <li>In these cases: MUST establish IV access for dextrose</li>
                        </ul>
                    </li>
                </ul>
            </li>
            <li><strong>Recheck BSL 15 minutes after treatment</strong> - repeat if still <4.0 mmol/L</li>
            <li><strong>Once conscious:</strong> Give complex carbohydrate meal (sandwich, crackers, milk) to prevent recurrence</li>
            <li><strong>Investigate cause:</strong> Medication error, missed meal, exercise, alcohol, infection</li>
            <li><strong>Adjust diabetes medications:</strong> Review insulin/sulfonylurea doses to prevent recurrence</li>
            <li><strong>Observe:</strong> At least 4 hours (longer if sulfonylurea-induced - may recur for 24-48 hours)</li>
        </ul>

        <h4>Prevention & Education</h4>

        <ul>
            <li>Always carry quick-acting carbs</li>
            <li>Wear MedicAlert bracelet</li>
            <li>Check BGL before driving (must be >5.0 mmol/L)</li>
            <li>Educate family/colleagues on glucagon use</li>
            <li>Adjust insulin doses for exercise, alcohol, illness</li>
        </ul>

        <h2 id="medications">PART 3: MEDICATION MANAGEMENT (AUSTRALIAN CONTEXT)</h2>

        <div class="alert alert-info">
            <strong>eTG 2024 First-Line:</strong> Metformin is the first-line oral agent for Type 2 Diabetes unless contraindicated. All medications listed include PBS (Pharmaceutical Benefits Scheme) criteria for Australian prescribing.
        </div>

        <h3>A. Oral Hypoglycaemic Agents</h3>

        <h4>1. Metformin (Biguanide) - FIRST-LINE</h4>

        <p><strong>Mechanism:</strong> Reduces hepatic glucose production, increases insulin sensitivity</p>

        <p><strong>PBS Criteria:</strong> Unrestricted for Type 2 Diabetes</p>

        <p><strong>Dosing:</strong></p>
        <ul>
            <li><strong>BEFORE STARTING:</strong> Check eGFR &gt;45 mL/min/1.73m¬≤ (MANDATORY - do NOT start if eGFR &lt;45)</li>
            <li>Start: 500mg daily with food (or 250-500mg daily in elderly/at risk of lactic acidosis)</li>
            <li>Titrate: Increase to 500mg twice daily after 1 week if tolerated, then to 1000mg twice daily after further 1-2 weeks</li>
            <li>Target: 1000mg twice daily (maximum 3000mg/day in divided doses)</li>
            <li>Use modified-release formulation if GI side effects persist</li>
            <li><strong>ONGOING MONITORING:</strong> Check eGFR every 3-6 months. Cease if eGFR &lt;30. Reduce dose if eGFR 30-45</li>
        </ul>

        <p><strong>Benefits:</strong></p>
        <ul>
            <li>Lowers HbA1c by 10-20 mmol/mol (~1-2%)</li>
            <li>Weight neutral or modest weight loss</li>
            <li>NO hypoglycaemia risk</li>
            <li>Cardiovascular benefits</li>
            <li>Inexpensive</li>
        </ul>

        <p><strong>Side Effects:</strong></p>
        <ul>
            <li>GI upset (nausea, diarrhoea) - common, usually resolves</li>
            <li>Vitamin B12 deficiency (long-term use)</li>
            <li>Lactic acidosis (RARE, if contraindications ignored)</li>
        </ul>

        <p><strong>Contraindications:</strong></p>
        <ul>
            <li>eGFR <30 ml/min (caution if <45 ml/min - reduce dose)</li>
            <li>Severe liver disease</li>
            <li>Hypoxic states (heart failure, respiratory failure)</li>
            <li>Alcohol excess</li>
            <li>Contrast studies (cease 48 hours before, restart when eGFR normal)</li>
        </ul>

        <h4>2. Sulfonylureas (e.g., Gliclazide)</h4>

        <p><strong>Mechanism:</strong> Stimulates pancreatic insulin secretion</p>

        <p><strong>PBS Criteria:</strong> Unrestricted for Type 2 Diabetes</p>

        <p><strong>Dosing (Gliclazide MR):</strong></p>
        <ul>
            <li>Start: 30mg daily with breakfast</li>
            <li>Titrate: Increase by 30mg every 1-2 weeks</li>
            <li>Maximum: 120mg daily</li>
        </ul>

        <p><strong>Benefits:</strong></p>
        <ul>
            <li>Effective glucose lowering (HbA1c ‚Üì10-15 mmol/mol)</li>
            <li>Inexpensive</li>
            <li>Long history of use</li>
        </ul>

        <p><strong>Side Effects:</strong></p>
        <ul>
            <li><strong>Hypoglycaemia</strong> (especially in elderly, renal impairment)</li>
            <li>Weight gain (2-3 kg average)</li>
        </ul>

        <p><strong>Cautions:</strong></p>
        <ul>
            <li>Adjust dose in renal impairment</li>
            <li>Educate on hypoglycaemia risk</li>
            <li>Avoid if erratic eating patterns</li>
        </ul>

        <h4>3. DPP-4 Inhibitors (Gliptins - e.g., Sitagliptin, Linagliptin)</h4>

        <p><strong>Mechanism:</strong> Increase incretin hormones, enhance insulin secretion, reduce glucagon</p>

        <p><strong>PBS Criteria:</strong> Requires failure/intolerance to metformin OR eGFR <50 ml/min</p>

        <p><strong>Benefits:</strong></p>
        <ul>
            <li>Weight neutral</li>
            <li>Low hypoglycaemia risk</li>
            <li>Once daily dosing</li>
            <li>Safe in renal impairment (linagliptin preferred)</li>
        </ul>

        <p><strong>Side Effects:</strong></p>
        <ul>
            <li>Generally well tolerated</li>
            <li>Upper respiratory tract infections</li>
            <li>Rare: Pancreatitis</li>
        </ul>

        <h4>4. SGLT2 Inhibitors (Gliflozins - e.g., Empagliflozin, Dapagliflozin)</h4>

        <p><strong>Mechanism:</strong> Block glucose reabsorption in kidney ‚Üí glycosuria</p>

        <p><strong>PBS Criteria (STRICT):</strong></p>
        <ul>
            <li>HbA1c ‚â•53 mmol/mol despite maximum tolerated metformin ¬± one other agent</li>
            <li>BMI ‚â•30 kg/m¬≤ (or ‚â•27 kg/m¬≤ if cardiovascular disease)</li>
            <li>eGFR ‚â•45 ml/min (for glucose-lowering indication)</li>
        </ul>

        <p><strong>Benefits:</strong></p>
        <ul>
            <li>Weight loss (2-4 kg)</li>
            <li>BP reduction</li>
            <li><strong>Cardiovascular benefits</strong> (reduced heart failure, CV death)</li>
            <li><strong>Renal protection</strong> (slow CKD progression)</li>
            <li>Low hypoglycaemia risk</li>
        </ul>

        <p><strong>Side Effects:</strong></p>
        <ul>
            <li>Genital candidiasis (common, especially women)</li>
            <li>UTIs</li>
            <li>Polyuria</li>
            <li>Rare: Euglycaemic DKA, Fournier's gangrene</li>
        </ul>

        <h4>5. GLP-1 Receptor Agonists (e.g., Dulaglutide, Semaglutide)</h4>

        <p><strong>Mechanism:</strong> Injectable incretin mimetic - enhances insulin, suppresses glucagon, slows gastric emptying</p>

        <p><strong>PBS Criteria (STRICT):</strong></p>
        <ul>
            <li>HbA1c ‚â•58 mmol/mol despite metformin + sulfonylurea</li>
            <li>BMI ‚â•30 kg/m¬≤ (or ‚â•27 kg/m¬≤ if cardiovascular disease)</li>
            <li>Authorisation required</li>
        </ul>

        <p><strong>Route:</strong> Subcutaneous injection (weekly or daily depending on agent)</p>

        <p><strong>Benefits:</strong></p>
        <ul>
            <li>Significant weight loss (4-6 kg)</li>
            <li>HbA1c reduction 10-20 mmol/mol</li>
            <li>Cardiovascular benefits</li>
            <li>Low hypoglycaemia risk (unless combined with sulfonylurea/insulin)</li>
        </ul>

        <p><strong>Side Effects:</strong></p>
        <ul>
            <li>Nausea (common initially, improves)</li>
            <li>Vomiting, diarrhoea</li>
            <li>Rare: Pancreatitis, thyroid C-cell tumours (animal data)</li>
        </ul>

        <h3>B. Insulin Therapy</h3>

        <h4>Types of Insulin (Australian Brands)</h4>

        <table>
            <thead>
                <tr>
                    <th>Type</th>
                    <th>Examples</th>
                    <th>Onset</th>
                    <th>Peak</th>
                    <th>Duration</th>
                    <th>Use</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Rapid-acting</strong></td>
                    <td>NovoRapid, Humalog, Apidra</td>
                    <td>5-15 min</td>
                    <td>1-2 hours</td>
                    <td>4-6 hours</td>
                    <td>Bolus (mealtime)</td>
                </tr>
                <tr>
                    <td><strong>Short-acting</strong></td>
                    <td>Actrapid, Humulin R</td>
                    <td>30 min</td>
                    <td>2-4 hours</td>
                    <td>6-8 hours</td>
                    <td>Bolus (older regimens)</td>
                </tr>
                <tr>
                    <td><strong>Intermediate</strong></td>
                    <td>Protaphane (NPH), Humulin NPH</td>
                    <td>1-2 hours</td>
                    <td>4-6 hours</td>
                    <td>12-18 hours</td>
                    <td>Basal (twice daily)</td>
                </tr>
                <tr>
                    <td><strong>Long-acting</strong></td>
                    <td>Lantus, Levemir</td>
                    <td>2-4 hours</td>
                    <td>No peak</td>
                    <td>20-24 hours</td>
                    <td>Basal (once daily)</td>
                </tr>
                <tr>
                    <td><strong>Ultra-long</strong></td>
                    <td>Toujeo, Tresiba</td>
                    <td>6 hours</td>
                    <td>No peak</td>
                    <td>>24 hours</td>
                    <td>Basal (once daily)</td>
                </tr>
                <tr>
                    <td><strong>Premixed</strong></td>
                    <td>NovoMix 30, Humalog Mix 25</td>
                    <td>Varies</td>
                    <td>Varies</td>
                    <td>12-24 hours</td>
                    <td>Twice daily regimen</td>
                </tr>
            </tbody>
        </table>

        <h4>Insulin Regimens</h4>

        <p><strong>1. Basal-Only (Starting regimen for Type 2):</strong></p>
        <ul>
            <li>Long-acting insulin once daily (bedtime or morning)</li>
            <li>Continue oral agents</li>
            <li>Starting dose: 10 units or 0.1-0.2 units/kg</li>
            <li>Titrate: Increase 2 units every 3 days until fasting glucose 4-7 mmol/L</li>
        </ul>

        <p><strong>2. Basal-Bolus (Most physiological - Type 1 and advanced Type 2):</strong></p>
        <ul>
            <li>Long-acting insulin once daily (basal)</li>
            <li>Rapid-acting insulin before each meal (bolus)</li>
            <li>Typical ratio: 50% basal, 50% bolus (divided across 3 meals)</li>
            <li>Requires carbohydrate counting</li>
        </ul>

        <p><strong>3. Premixed Insulin (Twice daily - simpler for some patients):</strong></p>
        <ul>
            <li>Before breakfast and before dinner</li>
            <li>Fixed ratio limits flexibility</li>
            <li>Starting dose: 10-12 units twice daily</li>
        </ul>

        <h4>PBS Criteria for Insulin</h4>

        <p><strong>Type 1 Diabetes:</strong> Unrestricted (all insulin types)</p>

        <p><strong>Type 2 Diabetes:</strong> PBS subsidy requires:</p>
        <ul>
            <li>HbA1c >53 mmol/mol despite maximum tolerated oral therapy OR</li>
            <li>Contraindications to oral therapy OR</li>
            <li>Pregnancy/planning pregnancy</li>
        </ul>

        <h4>Insulin Initiation Counselling</h4>

        <div class="script-box">
            <p><strong>Explaining Insulin (Word-for-word):</strong></p>
            <p>"I know starting insulin can feel overwhelming, and you may have concerns. Let me reassure you - insulin is a natural hormone that everyone's body makes. In Type 2 diabetes, your pancreas isn't making enough insulin anymore, despite the tablets. Insulin will help control your sugar levels and prevent complications."</p>

            <p><strong>Addressing Common Fears:</strong></p>
            <ul>
                <li><strong>"Will I be on insulin forever?"</strong> - "Most people with Type 2 diabetes do stay on insulin long-term, as it's very effective. However, if you lose significant weight or your pancreas function improves, we can reassess."</li>
                <li><strong>"Will the injections hurt?"</strong> - "The needles are very fine - much thinner than blood test needles. Most people say they barely feel it. I'll show you the proper technique."</li>
                <li><strong>"Does this mean my diabetes is worse?"</strong> - "Not necessarily 'worse', but it does mean your diabetes needs more support now. This is a natural progression for many people with Type 2 diabetes."</li>
            </ul>
        </div>

        <h4>Injection Technique Teaching</h4>

        <div class="script-box">
            <p><strong>Step-by-Step Insulin Injection (Say out loud to patient):</strong></p>
            <ol>
                <li><strong>"First, wash your hands thoroughly with soap and water."</strong></li>
                <li><strong>"Check the insulin pen:"</strong> Make sure it's the correct type and not expired. If it's long-acting insulin, roll gently between your palms - don't shake.</li>
                <li><strong>"Attach a new needle:"</strong> Remove the outer cap, screw on the needle, then remove the inner cap. We use a new needle every time.</li>
                <li><strong>"Prime the pen:"</strong> Dial to 2 units, point the needle up, tap to remove air bubbles, press the button until a drop appears. This confirms the pen is working.</li>
                <li><strong>"Dial your dose:"</strong> Turn the dial to your prescribed dose. Double-check it's correct.</li>
                <li><strong>"Choose an injection site:"</strong> Abdomen (5cm away from belly button) is best absorbed, or upper thigh, upper arm, or buttocks. Rotate sites to prevent lumps.</li>
                <li><strong>"Pinch the skin:"</strong> Gently pinch about 2-3cm of skin and fat between thumb and finger.</li>
                <li><strong>"Insert the needle:"</strong> Push the needle straight in at 90 degrees (or 45 degrees if very thin). It should go in smoothly.</li>
                <li><strong>"Inject the insulin:"</strong> Press the button all the way down until it stops. Keep it pressed.</li>
                <li><strong>"Count to 10:"</strong> Keep the needle in and the button pressed while counting slowly to 10. This ensures all the insulin goes in.</li>
                <li><strong>"Remove the needle:"</strong> Pull straight out, release the pinch, don't rub the area.</li>
                <li><strong>"Dispose safely:"</strong> Remove the needle and put it in your sharps container immediately. Never recap.</li>
                <li><strong>"Record the dose:"</strong> Write down the dose and time in your diabetes diary.</li>
            </ol>
        </div>

        <h4>Safety-Netting for Insulin</h4>

        <div class="alert alert-danger">
            <p><strong>RED FLAGS - When to seek immediate help:</strong></p>
            <ul>
                <li><strong>Severe hypoglycaemia:</strong> Confusion, unable to treat yourself, seizure, loss of consciousness - CALL 000</li>
                <li><strong>Very high glucose >20 mmol/L with:</strong> Vomiting, abdominal pain, fruity breath, rapid breathing - EMERGENCY DEPARTMENT (possible DKA)</li>
                <li><strong>Persistent hyperglycaemia:</strong> >15 mmol/L for 2+ days despite insulin - GP review urgently</li>
                <li><strong>Signs of infection:</strong> Fever, wound not healing - see GP (may need to increase insulin)</li>
                <li><strong>Unable to eat/vomiting:</strong> Continue long-acting insulin, reduce/omit rapid-acting, check BGL 2-4 hourly, seek advice</li>
            </ul>
        </div>

        <h3>C. Medication Algorithm (eTG 2024)</h3>

        <div class="tip-box">
            <p><strong>Type 2 Diabetes Management Algorithm (Australian eTG 2024):</strong></p>

            <p><strong>Step 1: LIFESTYLE MODIFICATION (All patients)</strong></p>
            <ul>
                <li>Diet: Australian Dietary Guidelines, carbohydrate quality and quantity</li>
                <li>Physical activity: 150 minutes/week moderate intensity</li>
                <li>Weight loss: 5-10% if overweight/obese</li>
                <li>Target HbA1c: <53 mmol/mol (7%) - reassess in 3 months</li>
            </ul>

            <p><strong>Step 2: If HbA1c ‚â•48 mmol/mol (6.5%) ‚Üí Add METFORMIN</strong></p>
            <ul>
                <li>First-line unless contraindicated</li>
                <li>Start 500mg daily, titrate to 1000mg BD</li>
                <li>Reassess in 3 months</li>
            </ul>

            <p><strong>Step 3: If HbA1c ‚â•53 mmol/mol (7%) ‚Üí Add Second Agent</strong></p>
            <ul>
                <li><strong>If CVD/CKD:</strong> Prefer SGLT2 inhibitor (if eGFR adequate) or GLP-1 agonist</li>
                <li><strong>If BMI >30:</strong> Prefer GLP-1 agonist or SGLT2 inhibitor (weight loss benefit)</li>
                <li><strong>If cost/access issue:</strong> Sulfonylurea or DPP-4 inhibitor</li>
                <li>Reassess in 3-6 months</li>
            </ul>

            <p><strong>Step 4: If HbA1c ‚â•58 mmol/mol (7.5%) ‚Üí Add Third Agent or Start Insulin</strong></p>
            <ul>
                <li>Triple therapy: Metformin + two other agents (consider PBS criteria)</li>
                <li>OR commence basal insulin if poor control</li>
            </ul>

            <p><strong>Step 5: Intensify Insulin</strong></p>
            <ul>
                <li>Basal-only ‚Üí Basal-bolus regimen</li>
                <li>Continue metformin (synergistic effect, reduce insulin dose needed)</li>
                <li>May continue SGLT2 inhibitor (CV/renal benefits)</li>
            </ul>
        </div>

        <h2 id="complications">PART 4: COMPLICATIONS ASSESSMENT</h2>

        <div class="alert alert-warning">
            <strong>Annual Screening Mandatory:</strong> All patients with diabetes require annual comprehensive complications screening as per RACGP/Diabetes Australia guidelines.
        </div>

        <h3>Microvascular Complications</h3>

        <h4>1. Diabetic Retinopathy</h4>

        <p><strong>Screening:</strong></p>
        <ul>
            <li><strong>Type 1:</strong> Annual screening from 5 years after diagnosis</li>
            <li><strong>Type 2:</strong> Annual screening from diagnosis</li>
            <li><strong>Method:</strong> Dilated fundoscopy or retinal photography by optometrist/ophthalmologist</li>
        </ul>

        <p><strong>Stages:</strong></p>
        <ul>
            <li><strong>Background retinopathy:</strong> Microaneurysms, dot/blot haemorrhages, hard exudates</li>
            <li><strong>Pre-proliferative:</strong> Cotton wool spots, venous beading</li>
            <li><strong>Proliferative:</strong> New vessel formation (requires laser treatment)</li>
            <li><strong>Maculopathy:</strong> Affects central vision (can occur at any stage)</li>
        </ul>

        <p><strong>Management:</strong></p>
        <ul>
            <li>Optimize glucose control (HbA1c <53 mmol/mol)</li>
            <li>Optimize BP control (<140/90 mmHg)</li>
            <li>Laser photocoagulation for proliferative or severe background</li>
            <li>Anti-VEGF injections for macular oedema</li>
            <li>Urgent ophthalmology referral if sight-threatening</li>
        </ul>

        <h4>2. Diabetic Nephropathy</h4>

        <p><strong>Screening (Annual):</strong></p>
        <ul>
            <li><strong>Urinary ACR (Albumin:Creatinine Ratio):</strong> First morning urine preferred</li>
            <li><strong>eGFR:</strong> From serum creatinine</li>
        </ul>

        <p><strong>Classification:</strong></p>
        <table>
            <thead>
                <tr>
                    <th>Stage</th>
                    <th>ACR (mg/mmol)</th>
                    <th>eGFR (ml/min/1.73m¬≤)</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Normal</td>
                    <td><2.5 (men), <3.5 (women)</td>
                    <td>>90</td>
                </tr>
                <tr>
                    <td>Microalbuminuria</td>
                    <td>2.5-25 (men), 3.5-35 (women)</td>
                    <td>60-89</td>
                </tr>
                <tr>
                    <td>Macroalbuminuria</td>
                    <td>>25 (men), >35 (women)</td>
                    <td>30-59</td>
                </tr>
                <tr>
                    <td>Kidney failure</td>
                    <td>Variable</td>
                    <td><30</td>
                </tr>
            </tbody>
        </table>

        <p><strong>Management:</strong></p>
        <ul>
            <li><strong>ACE inhibitor or ARB:</strong> First-line for albuminuria (renoprotective even if normotensive)</li>
            <li><strong>Target BP:</strong> <130/80 mmHg if albuminuria</li>
            <li><strong>SGLT2 inhibitor:</strong> Proven renal protection (slow eGFR decline)</li>
            <li><strong>Lipid management:</strong> Statin for CVD risk reduction</li>
            <li><strong>Avoid nephrotoxins:</strong> NSAIDs, contrast (if eGFR <30)</li>
            <li><strong>Nephrology referral:</strong> If eGFR <30 or rapidly declining</li>
        </ul>

        <h4>3. Diabetic Neuropathy</h4>

        <p><strong>Types:</strong></p>
        <ul>
            <li><strong>Peripheral neuropathy:</strong> Glove-and-stocking distribution (most common)</li>
            <li><strong>Autonomic neuropathy:</strong> Affects heart, GI, bladder, sexual function</li>
            <li><strong>Focal neuropathy:</strong> Single nerve (e.g., cranial nerve palsy, carpal tunnel)</li>
        </ul>

        <p><strong>Screening (Annual):</strong></p>
        <ul>
            <li><strong>10g monofilament testing:</strong> Test 4 sites on each foot (hallux, 1st, 3rd, 5th metatarsal heads)</li>
            <li><strong>Vibration sense:</strong> 128 Hz tuning fork on hallux</li>
            <li><strong>Ankle reflexes:</strong> Often absent in neuropathy</li>
            <li><strong>Symptom enquiry:</strong> Numbness, tingling, burning pain (worse at night)</li>
        </ul>

        <p><strong>Foot Examination (CRITICAL):</strong></p>
        <ul>
            <li>Inspect for: Calluses, corns, ulcers, deformities (Charcot foot), fungal infection</li>
            <li>Palpate: Dorsalis pedis and posterior tibial pulses</li>
            <li>Assess: Skin temperature, colour, hair distribution</li>
        </ul>

        <p><strong>Management:</strong></p>
        <ul>
            <li><strong>Optimize glucose control:</strong> May prevent progression</li>
            <li><strong>Neuropathic pain:</strong>
                <ul>
                    <li>First-line: Amitriptyline 10-75mg nocte OR Duloxetine 60mg daily OR Pregabalin 75-300mg BD</li>
                    <li>Topical: Capsaicin cream for localized pain</li>
                </ul>
            </li>
            <li><strong>Foot care education:</strong>
                <ul>
                    <li>Daily foot inspection</li>
                    <li>Appropriate footwear (no barefoot walking)</li>
                    <li>Podiatry referral (annual or more frequent if high risk)</li>
                    <li>Immediate review for any foot wounds</li>
                </ul>
            </li>
        </ul>

        <h3>Macrovascular Complications</h3>

        <h4>Cardiovascular Disease (CVD)</h4>

        <p><strong>Risk Assessment:</strong></p>
        <ul>
            <li>Diabetes itself is a CVD risk factor</li>
            <li>Assess other risk factors: Smoking, hypertension, dyslipidaemia, family history</li>
            <li>Calculate absolute CVD risk (Australian CVD risk calculator)</li>
        </ul>

        <p><strong>Screening:</strong></p>
        <ul>
            <li><strong>Annual:</strong> BP, lipids (total cholesterol, LDL, HDL, triglycerides)</li>
            <li><strong>ECG:</strong> At diagnosis, then as clinically indicated</li>
            <li><strong>Symptom enquiry:</strong> Chest pain, dyspnoea, palpitations</li>
        </ul>

        <p><strong>Management:</strong></p>
        <ul>
            <li><strong>BP target:</strong> <140/90 mmHg (or <130/80 if albuminuria)</li>
            <li><strong>Lipid target:</strong> LDL <2.0 mmol/L (or <1.8 if very high risk)</li>
            <li><strong>Antiplatelet:</strong> Aspirin 100mg daily if CVD or high risk (>60 years + 1 other risk factor)</li>
            <li><strong>Statin:</strong> All patients with Type 2 diabetes >40 years OR any age with albuminuria/CVD</li>
            <li><strong>ACE inhibitor/ARB:</strong> If hypertension or albuminuria</li>
        </ul>

        <h4>Peripheral Vascular Disease (PVD)</h4>

        <p><strong>Screening:</strong></p>
        <ul>
            <li>Palpate foot pulses (dorsalis pedis, posterior tibial)</li>
            <li>Assess capillary refill time</li>
            <li>Enquire: Intermittent claudication (calf pain on walking, relieved by rest)</li>
        </ul>

        <p><strong>Management:</strong></p>
        <ul>
            <li>Smoking cessation (MOST IMPORTANT)</li>
            <li>Supervised exercise program</li>
            <li>Antiplatelet therapy</li>
            <li>Statin</li>
            <li>Vascular surgery referral if severe</li>
        </ul>

        <h3>Complications Screening Schedule Summary</h3>

        <table>
            <thead>
                <tr>
                    <th>Complication</th>
                    <th>Screening Test</th>
                    <th>Frequency</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Retinopathy</strong></td>
                    <td>Dilated fundoscopy/retinal photos</td>
                    <td>Annual (from diagnosis Type 2, 5 years after diagnosis Type 1)</td>
                </tr>
                <tr>
                    <td><strong>Nephropathy</strong></td>
                    <td>ACR + eGFR</td>
                    <td>Annual</td>
                </tr>
                <tr>
                    <td><strong>Neuropathy</strong></td>
                    <td>Monofilament, vibration, foot exam</td>
                    <td>Annual</td>
                </tr>
                <tr>
                    <td><strong>CVD</strong></td>
                    <td>BP, lipids, ECG</td>
                    <td>BP every visit, lipids annual, ECG as needed</td>
                </tr>
                <tr>
                    <td><strong>PVD</strong></td>
                    <td>Foot pulses, claudication symptoms</td>
                    <td>Annual</td>
                </tr>
                <tr>
                    <td><strong>Dental</strong></td>
                    <td>Dental review</td>
                    <td>6-monthly (periodontal disease risk)</td>
                </tr>
            </tbody>
        </table>

        <h2 id="osce-stations">PART 5: OSCE PRACTICE STATIONS</h2>

        <h3>Station 1: Newly Diagnosed Type 2 Diabetes Counselling</h3>

        <h4>FOR THE CANDIDATE (1 minute reading time)</h4>

        <div class="alert alert-info">
            <p><strong>Station Information:</strong></p>
            <p><strong>Time:</strong> 8 minutes</p>
            <p><strong>Task:</strong> Counsel a patient about their new diagnosis of Type 2 Diabetes</p>

            <p><strong>Clinical Information:</strong></p>
            <p>Mr John Chen, 58-year-old accountant, has attended for review of recent blood tests. His fasting glucose was 8.2 mmol/L and HbA1c 64 mmol/mol (8.0%). He has no symptoms but was tested due to family history of diabetes. BMI 32 kg/m¬≤. BP 145/90 mmHg.</p>

            <p><strong>Your tasks:</strong></p>
            <ol>
                <li>Explain the diagnosis of Type 2 Diabetes</li>
                <li>Discuss initial management (lifestyle + medication)</li>
                <li>Explain the importance of screening for complications</li>
                <li>Address the patient's concerns</li>
            </ol>
        </div>

        <h4>FOR THE SIMULATED PATIENT</h4>

        <p><strong>Background:</strong> You are John Chen, a 58-year-old accountant. You feel well and came in for blood tests only because your brother was recently diagnosed with diabetes. You're shocked to hear you might have diabetes too.</p>

        <p><strong>Concerns to raise:</strong></p>
        <ul>
            <li>"I feel completely fine - are you sure there's not a mistake with the blood test?"</li>
            <li>"My brother has to take insulin - will I need that?"</li>
            <li>"I've heard diabetes means you can go blind or lose your feet - is that true?"</li>
            <li>"I'm quite busy with work - how much time will managing this take?"</li>
        </ul>

        <p><strong>Emotional state:</strong> Anxious, in denial initially, but willing to listen if doctor explains clearly</p>

        <h4>FOR THE EXAMINER - MARKING CHECKLIST</h4>

        <table>
            <thead>
                <tr>
                    <th>Domain</th>
                    <th>Criteria</th>
                    <th>‚úì</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td rowspan="3"><strong>1. Introduction & Rapport (2 marks)</strong></td>
                    <td>Introduces self, confirms patient identity</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Establishes what patient already knows</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Empathetic, allows patient to express concerns</td>
                    <td></td>
                </tr>
                <tr>
                    <td rowspan="4"><strong>2. Explaining Diagnosis (3 marks)</strong></td>
                    <td>Explains diabetes in lay terms (body not processing sugar properly)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Mentions HbA1c result and what it means (average sugar over 3 months)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Explains asymptomatic diabetes is common</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Reassures that it's manageable with treatment</td>
                    <td></td>
                </tr>
                <tr>
                    <td rowspan="5"><strong>3. Lifestyle Management (4 marks)</strong></td>
                    <td>Discusses diet (reduce refined carbs, portion control) - Australian Dietary Guidelines</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Discusses weight loss (5-10% target mentioned)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Discusses exercise (150 minutes/week, moderate intensity)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Offers dietitian referral</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Mentions NDSS (National Diabetes Services Scheme) referral</td>
                    <td></td>
                </tr>
                <tr>
                    <td rowspan="3"><strong>4. Medication Management (3 marks)</strong></td>
                    <td>Explains need for Metformin (first-line, evidence-based)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Discusses common side effects (GI upset, usually temporary)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Reassures insulin not immediately necessary for Type 2</td>
                    <td></td>
                </tr>
                <tr>
                    <td rowspan="3"><strong>5. Complications Screening (2 marks)</strong></td>
                    <td>Explains importance of annual eye checks (prevent blindness)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Mentions kidney function and foot checks</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Reassures early detection and treatment prevent complications</td>
                    <td></td>
                </tr>
                <tr>
                    <td rowspan="3"><strong>6. Follow-up & Safety-Netting (2 marks)</strong></td>
                    <td>Arranges review in 3 months (recheck HbA1c)</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Provides written information/NDSS resources</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Invites questions, checks understanding</td>
                    <td></td>
                </tr>
                <tr>
                    <td rowspan="2"><strong>7. Communication Skills (2 marks)</strong></td>
                    <td>Uses plain language, avoids jargon, checks understanding</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Empathetic, addresses patient's specific concerns</td>
                    <td></td>
                </tr>
            </tbody>
        </table>

        <p><strong>Total: 18 marks</strong></p>
        <p><strong>Pass Mark: 12/18 (67%)</strong></p>

        <h3>Station 2: Insulin Initiation Counselling</h3>

        <h4>FOR THE CANDIDATE (1 minute reading time)</h4>

        <div class="alert alert-info">
            <p><strong>Station Information:</strong></p>
            <p><strong>Time:</strong> 8 minutes</p>
            <p><strong>Task:</strong> Counsel a patient about starting insulin therapy</p>

            <p><strong>Clinical Information:</strong></p>
            <p>Mrs Maria Nguyen, 65-year-old with Type 2 Diabetes for 8 years. Currently on Metformin 1000mg BD + Gliclazide 120mg daily. Recent HbA1c 75 mmol/mol (9.0%). Experiencing fatigue and blurred vision. You have decided to commence basal insulin (Lantus 10 units nocte).</p>

            <p><strong>Your tasks:</strong></p>
            <ol>
                <li>Explain why insulin is needed</li>
                <li>Demonstrate insulin injection technique (using demo pen)</li>
                <li>Discuss hypoglycaemia recognition and management</li>
                <li>Arrange follow-up and safety-netting</li>
            </ol>
        </div>

        <h4>FOR THE SIMULATED PATIENT</h4>

        <p><strong>Background:</strong> You are Maria Nguyen, 65 years old. You've had diabetes for 8 years and have been managing with tablets. You're very worried about starting insulin - you've heard it's the "last resort" and means your diabetes is much worse.</p>

        <p><strong>Concerns to raise:</strong></p>
        <ul>
            <li>"I'm really scared of needles - do I have to inject myself?"</li>
            <li>"My friend says once you start insulin, you can never come off it - is that true?"</li>
            <li>"Will I have to inject before every meal?"</li>
            <li>"What if my sugar drops too low and I pass out?"</li>
        </ul>

        <p><strong>Emotional state:</strong> Anxious, fearful, but willing to try if doctor reassures you</p>

        <h4>EXAMINER MARKING CHECKLIST (Summary)</h4>

        <p><strong>Key Criteria (18 marks total):</strong></p>
        <ol>
            <li>Introduction & rapport (2 marks)</li>
            <li>Explaining need for insulin - pancreas not making enough, not a failure (3 marks)</li>
            <li>Injection technique demonstration - 12-step process shown correctly (4 marks)</li>
            <li>Hypoglycaemia education - 15-15 rule, symptoms, carrying glucose (3 marks)</li>
            <li>Addressing needle fears - reassurance about fine needles, minimal pain (2 marks)</li>
            <li>Follow-up plan - weekly titration, NDSS support, diabetes educator (2 marks)</li>
            <li>Communication skills - empathy, plain language (2 marks)</li>
        </ol>

        <h3>Station 3: Hypoglycaemia Education</h3>

        <h4>FOR THE CANDIDATE (1 minute reading time)</h4>

        <div class="alert alert-info">
            <p><strong>Station Information:</strong></p>
            <p><strong>Time:</strong> 8 minutes</p>
            <p><strong>Task:</strong> Educate a patient about hypoglycaemia management</p>

            <p><strong>Clinical Information:</strong></p>
            <p>Mr David Thompson, 45-year-old with Type 1 Diabetes for 20 years. On basal-bolus insulin (NovoRapid + Lantus). Recently had two episodes of hypoglycaemia (BGL 3.2 and 2.8 mmol/L) when he skipped lunch. He wants to know how to prevent and manage low sugars.</p>

            <p><strong>Your tasks:</strong></p>
            <ol>
                <li>Explain hypoglycaemia symptoms</li>
                <li>Teach the 15-15 rule</li>
                <li>Discuss prevention strategies</li>
                <li>Explain when to seek emergency help</li>
            </ol>
        </div>

        <h4>EXAMINER MARKING CHECKLIST (Summary)</h4>

        <p><strong>Key Criteria (18 marks total):</strong></p>
        <ol>
            <li>Explains early symptoms - shaking, sweating, hunger, palpitations (2 marks)</li>
            <li>Explains late symptoms - confusion, drowsiness, seizure risk (2 marks)</li>
            <li>Teaches 15-15 rule correctly - 15g quick carbs, wait 15 min, recheck (4 marks)</li>
            <li>Lists appropriate quick-acting carbs - glucose tablets, juice, jelly beans (2 marks)</li>
            <li>Explains need for complex carbs after - sandwich, crackers (1 mark)</li>
            <li>Prevention strategies - regular meals, check before driving, adjust for exercise (3 marks)</li>
            <li>Driving safety - must be >5.0 mmol/L, carry glucose in car (2 marks)</li>
            <li>Emergency - glucagon kit, MedicAlert bracelet, when to call 000 (2 marks)</li>
        </ol>

        <h2 id="counseling">PART 6: COUNSELLING SCRIPTS (Word-for-Word)</h2>

        <h3>Script 1: Explaining Type 2 Diabetes Diagnosis</h3>

        <div class="script-box">
            <p><strong>Opening:</strong></p>
            <p>"Thank you for coming in today. I've received your blood test results and I need to discuss them with you. Is now a good time? Do you have someone with you, or would you like someone here for this conversation?"</p>

            <p><strong>Explaining the diagnosis:</strong></p>
            <p>"Your blood tests show that you have Type 2 Diabetes. I understand this might come as a shock. Let me explain what this means in simple terms."</p>

            <p>"Diabetes is a condition where your blood sugar levels are higher than they should be. Normally, when you eat food, your body breaks it down into sugar (glucose), which goes into your bloodstream. Your pancreas - an organ in your abdomen - makes a hormone called insulin, which helps move that sugar from your blood into your cells where it's used for energy."</p>

            <p>"In Type 2 Diabetes, two things are happening: First, your pancreas isn't making quite enough insulin. Second, your body isn't responding to insulin as well as it should - we call this 'insulin resistance'. This means the sugar stays in your blood instead of going into your cells, which is why your blood sugar is high."</p>

            <p><strong>The good news:</strong></p>
            <p>"The good news is that Type 2 Diabetes is very manageable. With the right treatment - which includes healthy eating, regular exercise, and sometimes medication - most people with diabetes live long, healthy lives. We've caught this early, which is excellent, because early treatment can prevent complications."</p>

            <p><strong>Checking understanding:</strong></p>
            <p>"Does this make sense so far? Do you have any questions about what I've explained?"</p>
        </div>

        <h3>Script 2: Lifestyle Modification Discussion</h3>

        <div class="script-box">
            <p><strong>Diet counselling:</strong></p>
            <p>"Let's talk about food first. I know you might be worried you'll have to completely change how you eat, but it's more about making gradual, sustainable changes rather than a strict 'diabetic diet'."</p>

            <p>"The key things are:</p>
            <ul>
                <li><strong>Choose better carbohydrates:</strong> Wholegrain bread instead of white bread, brown rice instead of white rice, wholemeal pasta. These release sugar more slowly into your blood.</li>
                <li><strong>Watch your portion sizes:</strong> A serving of carbohydrate should be about the size of your fist. Fill half your plate with vegetables, a quarter with protein (meat, fish, chicken, legumes), and a quarter with carbs.</li>
                <li><strong>Reduce sugary drinks and snacks:</strong> Regular soft drinks, fruit juice, lollies, cakes - these cause rapid spikes in blood sugar. Water, tea, or coffee without sugar are better choices.</li>
                <li><strong>Regular meals:</strong> Try to eat at similar times each day. Don't skip meals, especially if you're on medication.</li>
            </ul>

            <p>I'll arrange for you to see a dietitian who specializes in diabetes. They can work with you to create a meal plan that fits your lifestyle and food preferences. The Australian Dietary Guidelines have excellent resources too."</p>

            <p><strong>Exercise counselling:</strong></p>
            <p>"Physical activity is one of the best things you can do for diabetes. It helps your body use insulin better and lowers blood sugar. You don't need to run marathons - we're talking about moderate activity like brisk walking, swimming, cycling, or gardening."</p>

            <p>"The goal is 150 minutes per week - that's about 30 minutes, 5 days a week. You can break it up - even three 10-minute walks during the day count. The important thing is to find something you enjoy, so you'll stick with it."</p>

            <p>"Before you start any new exercise program, we should check your heart and feet to make sure it's safe. Do you have any physical limitations I should know about?"</p>

            <p><strong>Weight loss (if applicable):</strong></p>
            <p>"Research shows that losing even 5-10% of your body weight - that's about [calculate] kg for you - can significantly improve blood sugar control. Some people can even put their diabetes into remission with weight loss. We'll work together to set realistic goals and support you along the way."</p>
        </div>

        <h3>Script 3: Starting Metformin Counselling</h3>

        <div class="script-box">
            <p><strong>Explaining why medication is needed:</strong></p>
            <p>"Based on your HbA1c result of [X] mmol/mol, I think we should start you on a medication called Metformin alongside the lifestyle changes we discussed. Metformin is the first-line medication we use for Type 2 Diabetes - it's been used safely for over 60 years and has excellent evidence behind it."</p>

            <p><strong>How it works:</strong></p>
            <p>"Metformin works in two main ways: First, it reduces the amount of sugar your liver releases into your blood. Second, it helps your muscles and fat cells respond better to insulin. It doesn't make your pancreas produce more insulin, so it won't cause your blood sugar to drop too low."</p>

            <p><strong>Dosing:</strong></p>
            <p>"We'll start with a low dose - 500 milligrams once or twice daily with food - and gradually increase it over a few weeks. This 'start low, go slow' approach helps your body adjust and reduces side effects. The target dose is usually 1000 milligrams twice daily."</p>

            <p><strong>Side effects:</strong></p>
            <p>"The most common side effects are tummy upset - nausea, loose stools, or diarrhoea. About half of people get this, but the good news is it usually settles down after 1-2 weeks as your body adjusts. Taking the tablet with food helps. If it's still bothering you, we can try a modified-release version that's gentler on the stomach."</p>

            <p>"Rarely, some people get a metallic taste. Even more rarely, it can affect vitamin B12 absorption with long-term use, so we'll check that in your annual blood tests."</p>

            <p><strong>What to avoid:</strong></p>
            <p>"There are a few situations where we need to temporarily stop Metformin:</p>
            <ul>
                <li>If you need a CT scan with contrast dye - stop it 48 hours before and restart once your kidney function is checked</li>
                <li>If you're severely unwell with vomiting or diarrhoea and can't keep fluids down - stop it and contact me</li>
                <li>If you're having surgery with anaesthetic - your surgeon will advise</li>
            </ul>

            <p><strong>Monitoring:</strong></p>
            <p>"This medication is on the PBS (Pharmaceutical Benefits Scheme), so it's subsidised. We'll check your HbA1c in 3 months to see how well it's working. If you have any side effects that don't settle, please let me know before then - there are other options."</p>

            <p><strong>Checking understanding:</strong></p>
            <p>"Do you have any questions about the medication? Are you happy to give it a try?"</p>
        </div>

        <h2 id="guidelines">PART 7: AUSTRALIAN GUIDELINES SUMMARY</h2>

        <h3>eTG 2024 Management Summary</h3>

        <p><strong>Diagnostic Criteria (any ONE of):</strong></p>
        <ul>
            <li>Fasting glucose ‚â•7.0 mmol/L (on two occasions)</li>
            <li>HbA1c ‚â•48 mmol/mol (6.5%) (on two occasions)</li>
            <li>Random glucose ‚â•11.1 mmol/L (if symptomatic)</li>
            <li>OGTT 2-hour glucose ‚â•11.1 mmol/L</li>
        </ul>

        <p><strong>HbA1c Targets (Australian):</strong></p>
        <table>
            <thead>
                <tr>
                    <th>Population</th>
                    <th>HbA1c Target</th>
                    <th>Rationale</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Most adults with Type 2</td>
                    <td><53 mmol/mol (<7%)</td>
                    <td>Balance between reducing complications and minimizing hypoglycaemia</td>
                </tr>
                <tr>
                    <td>Newly diagnosed, long life expectancy</td>
                    <td><48 mmol/mol (<6.5%)</td>
                    <td>More aggressive early control may delay complications</td>
                </tr>
                <tr>
                    <td>Elderly/frail/limited life expectancy</td>
                    <td><64 mmol/mol (<8%)</td>
                    <td>Reduce hypoglycaemia risk, avoid overtreatment</td>
                </tr>
                <tr>
                    <td>History of severe hypoglycaemia</td>
                    <td><64 mmol/mol (<8%)</td>
                    <td>Safety priority</td>
                </tr>
                <tr>
                    <td>Type 1 diabetes (adults)</td>
                    <td><53 mmol/mol (<7%)</td>
                    <td>Prevent long-term complications</td>
                </tr>
                <tr>
                    <td>Pregnancy (Type 1 or Type 2)</td>
                    <td><36 mmol/mol (<5.5%)</td>
                    <td>Prevent fetal complications (tight control essential)</td>
                </tr>
            </tbody>
        </table>

        <h3>PBS Criteria Summary (2024)</h3>

        <table>
            <thead>
                <tr>
                    <th>Medication Class</th>
                    <th>PBS Criteria</th>
                    <th>Special Notes</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Metformin</strong></td>
                    <td>Unrestricted for Type 2 Diabetes</td>
                    <td>First-line agent</td>
                </tr>
                <tr>
                    <td><strong>Sulfonylureas</strong></td>
                    <td>Unrestricted for Type 2 Diabetes</td>
                    <td>Inexpensive option</td>
                </tr>
                <tr>
                    <td><strong>DPP-4 inhibitors</strong></td>
                    <td>Requires metformin failure OR eGFR <50 ml/min</td>
                    <td>Authority required</td>
                </tr>
                <tr>
                    <td><strong>SGLT2 inhibitors</strong></td>
                    <td>HbA1c ‚â•53 mmol/mol + max metformin ¬± 1 other agent<br>BMI ‚â•30 (or ‚â•27 with CVD)<br>eGFR ‚â•45 ml/min</td>
                    <td>Authority required<br>Can continue if eGFR falls below 45 (renal protection)</td>
                </tr>
                <tr>
                    <td><strong>GLP-1 agonists</strong></td>
                    <td>HbA1c ‚â•58 mmol/mol + metformin + sulfonylurea<br>BMI ‚â•30 (or ‚â•27 with CVD)</td>
                    <td>Authority required<br>Streamlined authority for some agents</td>
                </tr>
                <tr>
                    <td><strong>Insulin (Type 2)</strong></td>
                    <td>HbA1c >53 mmol/mol despite max oral therapy<br>OR contraindications to oral agents<br>OR pregnancy</td>
                    <td>Unrestricted for Type 1</td>
                </tr>
            </tbody>
        </table>

        <h3>NDSS (National Diabetes Services Scheme)</h3>

        <p><strong>What is NDSS?</strong></p>
        <p>Australian Government initiative providing subsidised diabetes products and support services to all Australians with diabetes.</p>

        <p><strong>Registration:</strong> FREE - online at ndss.com.au or by phone 1800 637 700</p>

        <p><strong>Benefits:</strong></p>
        <ul>
            <li>Subsidised blood glucose monitoring products (test strips, lancets, meters)</li>
            <li>Insulin syringes and pen needles (FREE if on insulin)</li>
            <li>Continuous glucose monitors (subsidised for Type 1 and eligible Type 2)</li>
            <li>Sharps disposal containers</li>
            <li>Access to diabetes educators</li>
            <li>Free educational resources and support programs</li>
        </ul>

        <p><strong>MANDATORY REFERRAL:</strong> All newly diagnosed patients MUST be registered with NDSS - this is an examiner expectation!</p>

        <h2 id="mistakes">PART 8: COMMON IMG MISTAKES ‚ùå</h2>

        <div class="mistake-box">
            <h3>1. Using US Units Instead of Australian Units ‚ùå</h3>
            <p><strong>Mistake:</strong> "Your blood glucose is 150 mg/dL"</p>
            <p><strong>Correct:</strong> "Your blood glucose is 8.3 mmol/L"</p>
            <p><strong>Impact:</strong> Immediate examiner concern - Australian doctors ONLY use mmol/L for glucose</p>
            <p><strong>Conversion:</strong> mg/dL √∑ 18 = mmol/L (e.g., 180 mg/dL = 10 mmol/L)</p>
        </div>

        <div class="mistake-box">
            <h3>2. Using American Terminology ‚ùå</h3>
            <p><strong>Mistakes:</strong></p>
            <ul>
                <li>"Go to the ER if..." ‚Üí "Go to the Emergency Department if..."</li>
                <li>"Acetaminophen for pain" ‚Üí "Paracetamol for pain"</li>
                <li>"Albuterol inhaler" ‚Üí "Salbutamol inhaler"</li>
                <li>"You have anemia" ‚Üí "You have anaemia"</li>
                <li>"Glucophage" (brand) ‚Üí "Metformin" (generic name preferred in Australia)</li>
            </ul>
            <p><strong>Impact:</strong> Demonstrates lack of Australian medical training - examiners notice immediately</p>
        </div>

        <div class="mistake-box">
            <h3>3. Not Mentioning PBS (Pharmaceutical Benefits Scheme) ‚ùå</h3>
            <p><strong>Mistake:</strong> Prescribing SGLT2 inhibitor or GLP-1 agonist without checking PBS criteria</p>
            <p><strong>Correct:</strong> "I'd like to start you on an SGLT2 inhibitor. This medication is on the PBS, but we need to meet certain criteria - your HbA1c needs to be over 53 mmol/mol despite being on metformin, and your BMI needs to be over 30, which you meet. I'll need to fill out an authority script."</p>
            <p><strong>Impact:</strong> PBS is central to Australian prescribing - ignoring it suggests unfamiliarity with Australian healthcare system</p>
        </div>

        <div class="mistake-box">
            <h3>4. Forgetting NDSS Referral ‚ùå</h3>
            <p><strong>Mistake:</strong> Counselling newly diagnosed patient without mentioning NDSS registration</p>
            <p><strong>Correct:</strong> "I'm going to register you with the NDSS - that's the National Diabetes Services Scheme. It's a free government program that provides subsidised blood testing equipment and gives you access to diabetes educators. You'll get a card in the mail, and then you can access these products from pharmacies."</p>
            <p><strong>Impact:</strong> NDSS is standard care in Australia - examiners expect this to be mentioned</p>
        </div>

        <div class="mistake-box">
            <h3>5. Incorrect HbA1c Interpretation ‚ùå</h3>
            <p><strong>Mistake:</strong> "Your HbA1c is 7.5" (using old percentage)</p>
            <p><strong>Correct:</strong> "Your HbA1c is 58 mmol/mol, which is equivalent to 7.5%. This is above our target of 53 mmol/mol."</p>
            <p><strong>Impact:</strong> Australia uses mmol/mol as primary unit (IFCC standard). Always state mmol/mol first</p>
        </div>

        <div class="mistake-box">
            <h3>6. Not Screening for Complications Annually ‚ùå</h3>
            <p><strong>Mistake:</strong> Managing diabetes without organizing annual eye/kidney/foot screening</p>
            <p><strong>Correct:</strong> "We need to screen for diabetes complications annually. I'll arrange: 1) Retinal photos or eye specialist visit, 2) Kidney function and urine test for protein, 3) Foot examination with monofilament testing, 4) Blood pressure and cholesterol check."</p>
            <p><strong>Impact:</strong> Complications screening is mandatory quality care - examiners look for this</p>
        </div>

        <div class="mistake-box">
            <h3>7. Using Wrong HbA1c Targets ‚ùå</h3>
            <p><strong>Mistake:</strong> Targeting HbA1c <48 mmol/mol (<6.5%) for 80-year-old frail patient on insulin</p>
            <p><strong>Correct:</strong> "For someone your age with other health conditions, we aim for an HbA1c under 64 mmol/mol (under 8%). Aiming too low increases your risk of hypoglycaemia, which can be dangerous."</p>
            <p><strong>Impact:</strong> Individualized targets demonstrate clinical judgment - one-size-fits-all approach is unsafe</p>
        </div>

        <div class="mistake-box">
            <h3>8. Forgetting Metformin Contraindications ‚ùå</h3>
            <p><strong>Mistake:</strong> Starting metformin without checking kidney function</p>
            <p><strong>Correct:</strong> "Before starting metformin, I need to check your kidney function. If your eGFR is below 30, we can't use metformin. If it's between 30-45, we need to reduce the dose."</p>
            <p><strong>Impact:</strong> Metformin + renal impairment = lactic acidosis risk - serious safety issue</p>
        </div>

        <div class="mistake-box">
            <h3>9. Not Offering Interpreter Services ‚ùå</h3>
            <p><strong>Mistake:</strong> Proceeding with complex diabetes education when patient has limited English</p>
            <p><strong>Correct:</strong> "I can see you're finding this difficult to follow. Would you like me to arrange an interpreter in [language]? We have telephone interpreters available immediately, or I can book an in-person interpreter for your next visit. It's very important you understand your diabetes management."</p>
            <p><strong>Impact:</strong> Interpreter services are FREE in Australian hospitals - not offering them is poor practice</p>
        </div>

        <div class="mistake-box">
            <h3>10. Missing Cultural Considerations for Diet ‚ùå</h3>
            <p><strong>Mistake:</strong> Generic "eat less bread and pasta" advice to patient from non-Western background</p>
            <p><strong>Correct:</strong> "Can you tell me about your typical meals? What does your family usually eat?" [Listen] "That's great. Rice is fine - we just need to watch portion sizes. Instead of white rice, try brown rice or basmati, which has a lower GI. Keep the same curries and vegetables you enjoy. The dietitian can help create a plan that fits your cultural foods."</p>
            <p><strong>Impact:</strong> Culturally sensitive care is essential - examiners assess this</p>
        </div>

        <div class="mistake-box">
            <h3>11. Confusing Type 1 and Type 2 Management ‚ùå</h3>
            <p><strong>Mistake:</strong> Telling Type 1 patient they can manage with diet and exercise</p>
            <p><strong>Correct:</strong> "Type 1 diabetes means your pancreas has stopped making insulin completely. This is different from Type 2 where the pancreas still makes some insulin. Because of this, you will ALWAYS need insulin - there's no way around it. Diet and exercise are still important, but they can't replace insulin in Type 1."</p>
            <p><strong>Impact:</strong> Dangerous misinformation - Type 1 patients will develop DKA without insulin</p>
        </div>

        <div class="mistake-box">
            <h3>12. Not Documenting Diabetes in Medical Records ‚ùå</h3>
            <p><strong>Mistake:</strong> Failing to update problem list, alert systems, or discharge summaries with diabetes diagnosis</p>
            <p><strong>Correct:</strong> Document in: 1) Problem list, 2) Medication alerts (if on insulin - hypoglycaemia risk), 3) Allergy section if sulfa allergy (can't use sulfonylureas), 4) Discharge summaries, 5) Referral letters</p>
            <p><strong>Impact:</strong> Continuity of care issue - other doctors need to know about diabetes</p>
        </div>

        <h2 id="references">PART 9: QUICK REFERENCE TABLES</h2>

        <h3>Oral Hypoglycaemic Agents Comparison</h3>

        <table>
            <thead>
                <tr>
                    <th>Class</th>
                    <th>Example</th>
                    <th>Mechanism</th>
                    <th>HbA1c ‚Üì</th>
                    <th>Weight</th>
                    <th>Hypo Risk</th>
                    <th>PBS</th>
                    <th>Cost</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Biguanide</td>
                    <td>Metformin</td>
                    <td>‚Üì hepatic glucose, ‚Üë insulin sensitivity</td>
                    <td>10-20 mmol/mol</td>
                    <td>Neutral/‚Üì</td>
                    <td>No</td>
                    <td>Unrestricted</td>
                    <td>$</td>
                </tr>
                <tr>
                    <td>Sulfonylurea</td>
                    <td>Gliclazide</td>
                    <td>‚Üë insulin secretion</td>
                    <td>10-15 mmol/mol</td>
                    <td>‚Üë (2-3kg)</td>
                    <td>Yes</td>
                    <td>Unrestricted</td>
                    <td>$</td>
                </tr>
                <tr>
                    <td>DPP-4i</td>
                    <td>Sitagliptin</td>
                    <td>‚Üë incretins</td>
                    <td>5-10 mmol/mol</td>
                    <td>Neutral</td>
                    <td>No</td>
                    <td>Metformin failure</td>
                    <td>$$</td>
                </tr>
                <tr>
                    <td>SGLT2i</td>
                    <td>Empagliflozin</td>
                    <td>‚Üë urinary glucose excretion</td>
                    <td>10-15 mmol/mol</td>
                    <td>‚Üì (2-4kg)</td>
                    <td>No</td>
                    <td>Strict (HbA1c, BMI)</td>
                    <td>$$$</td>
                </tr>
                <tr>
                    <td>GLP-1 agonist</td>
                    <td>Dulaglutide</td>
                    <td>‚Üë insulin, ‚Üì glucagon, slow gastric emptying</td>
                    <td>10-20 mmol/mol</td>
                    <td>‚Üì (4-6kg)</td>
                    <td>No*</td>
                    <td>Very strict</td>
                    <td>$$$$</td>
                </tr>
            </tbody>
        </table>
        <p><em>*Low hypo risk unless combined with sulfonylurea or insulin</em></p>

        <h3>Insulin Types Quick Reference</h3>

        <table>
            <thead>
                <tr>
                    <th>Type</th>
                    <th>Brand Examples</th>
                    <th>Onset</th>
                    <th>Peak</th>
                    <th>Duration</th>
                    <th>Appearance</th>
                    <th>When to Inject</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Rapid-acting</td>
                    <td>NovoRapid, Humalog</td>
                    <td>5-15 min</td>
                    <td>1-2 hrs</td>
                    <td>4-6 hrs</td>
                    <td>Clear</td>
                    <td>0-15 min before meals</td>
                </tr>
                <tr>
                    <td>Short-acting</td>
                    <td>Actrapid</td>
                    <td>30 min</td>
                    <td>2-4 hrs</td>
                    <td>6-8 hrs</td>
                    <td>Clear</td>
                    <td>30 min before meals</td>
                </tr>
                <tr>
                    <td>Intermediate</td>
                    <td>Protaphane (NPH)</td>
                    <td>1-2 hrs</td>
                    <td>4-6 hrs</td>
                    <td>12-18 hrs</td>
                    <td>Cloudy</td>
                    <td>Twice daily</td>
                </tr>
                <tr>
                    <td>Long-acting</td>
                    <td>Lantus, Levemir</td>
                    <td>2-4 hrs</td>
                    <td>No peak</td>
                    <td>20-24 hrs</td>
                    <td>Clear</td>
                    <td>Once daily, same time</td>
                </tr>
                <tr>
                    <td>Ultra-long</td>
                    <td>Toujeo, Tresiba</td>
                    <td>6 hrs</td>
                    <td>No peak</td>
                    <td>>24 hrs</td>
                    <td>Clear</td>
                    <td>Once daily, flexible time</td>
                </tr>
            </tbody>
        </table>

        <h3>HbA1c Conversion Table</h3>

        <table>
            <thead>
                <tr>
                    <th>HbA1c (mmol/mol)</th>
                    <th>HbA1c (%)</th>
                    <th>Estimated Average Glucose (mmol/L)</th>
                    <th>Interpretation</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>42</td>
                    <td>6.0</td>
                    <td>6.5</td>
                    <td>Normal (pre-diabetes threshold)</td>
                </tr>
                <tr>
                    <td>48</td>
                    <td>6.5</td>
                    <td>7.5</td>
                    <td>Diabetes diagnosis threshold</td>
                </tr>
                <tr>
                    <td>53</td>
                    <td>7.0</td>
                    <td>8.5</td>
                    <td>General target for most adults</td>
                </tr>
                <tr>
                    <td>58</td>
                    <td>7.5</td>
                    <td>9.5</td>
                    <td>Above target - intensify therapy</td>
                </tr>
                <tr>
                    <td>64</td>
                    <td>8.0</td>
                    <td>10.5</td>
                    <td>Target for elderly/frail</td>
                </tr>
                <tr>
                    <td>75</td>
                    <td>9.0</td>
                    <td>12.0</td>
                    <td>Poor control - urgent review</td>
                </tr>
                <tr>
                    <td>86</td>
                    <td>10.0</td>
                    <td>13.5</td>
                    <td>Very poor control - consider insulin</td>
                </tr>
            </tbody>
        </table>

        <footer>
            <p><strong>Document Created:</strong> December 16, 2025</p>
            <p><strong>Version:</strong> 1.0</p>
            <p><strong>Sources:</strong></p>
            <ul style="list-style: none; text-align: center;">
                <li>Murtagh's General Practice (8th Edition), Chapter 26</li>
                <li>Therapeutic Guidelines (eTG) 2024 - Endocrinology</li>
                <li>Australian Medicines Handbook (AMH) 2025</li>
                <li>RACGP Diabetes Management Guidelines</li>
                <li>Diabetes Australia Clinical Practice Guidelines</li>
                <li>PBS Schedule 2024</li>
            </ul>
            <p><em>For educational purposes - ICRP preparation at Young District Hospital, NSW Health</em></p>
            <p><strong>Aligned with:</strong> AHPRA Clinical Competency Standards | AMC Part 2 Clinical OSCE Format | Australian Medical Practice</p>
        </footer>
    </div>
</body>
</html>